Intellia Therapeutics
Intellia Therapeutics Inc is a clinical-stage biopharmaceutical enterprise headquartered in Cambridge, Massachusetts. The company specializes in developing curative therapies using CRISPR gene editing technology. Its research and clinical pipeline focuses on addressing the genetic basis of serious diseases by precisely editing target genes to restore biological function. Principal revenue is currently earned through research collaboration grants, development partnerships, and licensing agreements as its gene editing candidates advance through clinical trials. Intellia Therapeutics Inc is publicly listed on the Nasdaq Stock Market.
3 of the funds FundTelligence covers report a position in Intellia Therapeutics.
- Legal name
- Intellia Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 3
- Exposure themes
- Gene Editing, Genetic Medicine, Precision Medicine & Genomics
Funds holding Intellia Therapeutics
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)